Loading AI feed…

STOK

Rating neutralTentativeAI MemoPost-earnings T+1

Stoke Therapeutics

As of 2026-05-08/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

EMPEROR enrollment completion in June 2026 could de-risk the lead program • 2026-06-30

Base target: $35 / p=0% prob

Biggest risk

The counterpoint is that Q1 revenue fell to $6.2 million from a prior-year collaboration-heavy comparison, net loss widened to $50.0 million, and the story is still highly concentrated in one pivotal program with unproven Phase 3 efficacy. On T+1, no trustworthy post-print analyst target revisions were confirmed from checked sources, so there is limited external revision support for a stronger thesis change.

Invalidation

Break below $24 or thesis failure.

What would change my mind?

The strongest post-earnings read is that management combined new 4-year OLE cognition/behavior and seizure durability data with an EMPEROR enrollment-completion target for June 2026, while ending Q1 with $411.0 million of cash expected to fund operations into 2028. That keeps the lead-asset path intact and preserves optionality to the mid-2027 readout and planned NDA start. [#8-K-2026-05-07] [#10-Q-2026-05-07]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$35

p=0%

Bull target

$46

p=0%

Bear target

$24

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings digestion after mixed Q1 print and business update
Mid-2027 pivotal readout and planned rolling NDA start remain the real value inflection
The strongest post-earnings read is that management combined new 4-year OLE cognition/behavior and seizure durability data with an EMPEROR enrollment-completion target for June 2026, while ending Q1 with $411.0 million of cash expected to fund operations into 2028.

BearKey bullets

EMPEROR is still the central value driver, and Phase 3 efficacy/readout risk remains unresolved until mid-2027 despite June 2026 enrollment completion guidance.
[#8-K-2026-05-07]
Revenue remains lumpy and collaboration-dependent; Stoke still has no product sales and Q1 2026 revenue was down sharply from the prior-year Biogen-license recognition comparison.

WatchKey bullets

EMPEROR enrollment completion in June 2026 could de-risk the lead program

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $35 (p=0%)

Target spread vs base: +31% / -31%

Scenario probabilities

Bull Target: $46 (p=0%)Base Target: $35 (p=0%)Bear Target: $24 (p=0%)

Commentary

T+1 sentiment looks mixed but stable rather than strongly positive. Primary company news flow was constructive on long-term OLE data, EMPEROR progress, and runway, while the financial print itself was only modestly supportive because revenue was soft and losses remained elevated. The stock's May 8, 2026 session was described as muted versus the May 7 anchor close, and no confirmed post-print analyst target resets were available from checked sources; together with the packet's negative deterministic prior, that supports a tentative monitoring stance rather than a momentum call.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings digestion after mixed Q1 print and business update
Mid-2027 pivotal readout and planned rolling NDA start remain the real value inflection

Scenarios

Bull Target (Scenario probability)

$46 / p=0% prob

Base Target (Scenario probability)

$35 / p=0% prob

Bear Target (Scenario probability)

$24 / p=0% prob

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-06-30
EMPEROR enrollment completion in June 2026 could de-risk the lead program
Management said EMPEROR enrollment of approximately 150 patients is expected to complete in June 2026; as of May 5 about 130 patients had been randomized, with the remaining patients moving through screening. Hitting that milestone would modestly de-risk execution ahead of the pivotal readout, but it does not resolve efficacy risk. [#8-K-2026-05-07]
Prob 80.00% • Move 9.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Post-earnings digestion after mixed Q1 print and business update
2026-05-31
Q1 2026 results were mixed: net loss was $50.0 million, revenue was $6.2 million, cash was $411.0 million, and management reiterated runway into 2028 while highlighting durable long-term zorevunersen data and launch-readiness spending. Versus pre-print expectations around a roughly $0.80 loss and about $6.48 million to $7.07 million of revenue from secondary sources, the setup looks like a slight EPS beat with a modest revenue miss, which supports a cautious T+1 monitoring read rather than a standard-conviction thesis change. [#8-K-2026-05-07] [#10-Q-2026-05-07]
Prob 75% • Move 5% • Priced-in 70%

Long-term Catalysts

Months to a year

Mid-2027 pivotal readout and planned rolling NDA start remain the real value inflection
2027-06-30
Stoke expects mid-2027 data from EMPEROR to support completion of the planned rolling U.S. NDA submission, which management plans to initiate in Q1 2027. This is the main valuation driver because Stoke still has no approved product sales and the equity case remains concentrated in zorevunersen. [#8-K-2026-05-07] [#10-Q-2026-05-07]
Prob 55% • Move 38% • Priced-in 30%

Risks

EMPEROR is still the central value driver, and Phase 3 efficacy/readout risk remains unresolved until mid-2027 despite June 2026 enrollment completion guidance. [#8-K-2026-05-07]
Revenue remains lumpy and collaboration-dependent; Stoke still has no product sales and Q1 2026 revenue was down sharply from the prior-year Biogen-license recognition comparison. [#8-K-2026-05-07]
Runway improved to into 2028, but management states assumptions could prove wrong and capital could be used sooner than expected as clinical development and launch-readiness spending rise. [#10-Q-2026-05-07]
Safety monitoring remains important: elevated CSF protein lab values occurred in about 94% of patients and 59% were classified as treatment-emergent adverse events, even though no serious or severe clinical manifestations and no hydrocephalus were reported in the release. [#8-K-2026-05-07]
The quarter included $80.7 million raised through selective ATM sales of 2.6 million shares, which helps liquidity but adds dilution risk if future funding is needed. [#8-K-2026-05-07]

Peers

Symbol	Summary
INBX	Inhibrx Biosciences is a closer-size clinical biotech comp where valuation is also milestone-driven and commercial revenue is not the support; it is useful for binary-development and funding-risk framing, though the indication set is different.
MESO	Mesoblast is another development-stage biotech comp where regulatory and clinical milestones dominate valuation; it is an imperfect therapeutic comp but relevant for event-risk and runway sensitivity.
NBTX	Nanobiotix is a similarly sized clinical-stage biotech with partnership and trial-readout dependence; it is not a direct neuroscience peer, which reinforces that STOK's peer set is only moderately tight.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-08

AI Stock Memo: STOK - Stoke Therapeutics - RankAlpha